relevance of serum tumor markers
Post on 09-Apr-2018
224 Views
Preview:
TRANSCRIPT
-
8/8/2019 Relevance of Serum Tumor Markers
1/25
RELEVANCE OF SERUMTUMOR MARKERS
-
8/8/2019 Relevance of Serum Tumor Markers
2/25
1846 Bence-Jones protein
19401940 Acid phosphataseAcid phosphatase
1960 Immunoassay
19631963 AlphaAlpha--fetoproteinfetoprotein1965 Carcinoembryonic antigen
19751975 Monoclonal antibodiesMonoclonal antibodies
1980 CA 125, PSA, Carbohydrate antigens
19701970 OncogenesOncogenes1980 Tumor Suppressor Genes
20012001Microarrays, Mass Spectrometry, NeuralMicroarrays, Mass Spectrometry, Neural
Networks, Networks, MultiparametricMultiparametric AnalysisAnalysis
-
8/8/2019 Relevance of Serum Tumor Markers
3/25
Are substances usually proteins, that areproduced by the body in response to cancergrowth or by the cancer tissue itself and certain
benign (noncancerous) conditionsDetected in higher than normal amounts in theblood, urine, or body tissuesSome tumor markers are specific for one type of
cancer, while others are seen in several cancertypesMeasurements can be useful when used alongwith x-rays, or other tests in the detection and
diagnosis of some types of cancer
-
8/8/2019 Relevance of Serum Tumor Markers
4/25
H ighly specific : detectable in only one tumor typeH ighly sensitive : non-detectable in physiological orbenign disease statesLong lead-time : sufficient time for alteration ofnatural course of diseaseLevels correlate with tumor burden : prognostic &predictive utility of tumor markerShort half-life : frequent serial monitoring of markerlevels after 5-6 half-livesSimple and cheap test : applicability as screening testEasily obtainable specimens : acceptability by targetpopulation
I N REAL I TY AN ID EAL TUMOR MARKER D OES NOT EX I ST
-
8/8/2019 Relevance of Serum Tumor Markers
5/25
Serology Enzyme assaysImmunological Immunohistochemistry
Radioimmunoassay
Enzyme-linked immunosorbent assay
Flow cytometry
Cytogenetic analysis Flourescent in-situ hybridization
Spectral karyotyping
Comparative genomic hybridization
Genetic analysis Sequencing (automated)
Reverse transcriptionGel electrophoresis
DNA micro-array analysis
Proteomics Surface-enhanced laserdesorption/ionization
-
8/8/2019 Relevance of Serum Tumor Markers
6/25
CATEGORY SUBCATEGORY EXAMPLESO ncofetal antigens AFP, CEAH ormones Catecholamines, calcitonin,,
B-H CG
Glycoproteins CA125, CA15-3, CA19-9, CA72-4,PSA
Metabolites VMA, H IAA
Tumor-associated antigens Viral antigens Polyoma, SV 40
MH C-related antigens H -2k antigen
Enzymes NSE, PLAPO ncogene products C-myc, c-erbB2
Cytogenetic products Philadelphia chromosome
Tumor-associated markers Proteins Immunoglobulins, B-2M`
Enzymes Lactate dehydrogenase, alkaline
phosphatase, pteridines, pterinesAcute-phase proteins C-reactive protein, ferritin
Inflammatory markers ESR, viscosity
Ultrastructural components Intermediate filamentcomponents
Desmin, vimentin
-
8/8/2019 Relevance of Serum Tumor Markers
7/25
SCREEN I NG
DI AGNOS I S
PROGNOS I S: RECURRENCE,METASTAS I S AN D SURV I VAL
MON I TOR I NG TREATMENTRESPONSE
-
8/8/2019 Relevance of Serum Tumor Markers
8/25
Never rely on the result of a single test When ordering serial testing, be certain to order every test fromthe same laboratory using the same assay kit Be certain that the tumor marker selected for monitoring
recurrence was elevated in the patient prior to surgery Consider the half-life of the tumor marker when interpreting thetest result Consider how the tumor marker is removed from ormetabolized in the blood circulationConsider ordering multiple markers to improve both thesensitivity and the specificity for diagnosisBe aware of the presence of ectopic tumor markersHeterophile antibody
-
8/8/2019 Relevance of Serum Tumor Markers
9/25
A complex glycoprotein with a MW of approximately 180,000 daltons
First discovered in patients with adenocarcinoma of the colon in 1965
Metabolized primarily by the liver with a circulating half-life rangingfrom 1 to 8 days
H epatic diseases, including extrahepatic biliary obstruction,intrahepatic cholestasis and hepatocellular disease, may impedeclearance rate
Normally, it is present in the fetal intestine, pancreas and liverduring the first 2 trimesters of gestation
Normal colonic mucosa and pleural and lactating mammary tissuebind to anti-CEA antiserum; however, the quantity of CEA or CEA-like molecules expressed in these tissues is much less than thatobserved in malignant tumors
Normal range is from 0 to 2.5 to 3.0 ng/ml as determined byradioimmunoassays and increase serum concentrations
-
8/8/2019 Relevance of Serum Tumor Markers
10/25
Benign conditions that cause elevated CEA
Cigarette smoking BronchitisEmphysema GastritisGastric ulcer H epatic diseasePancreatitis Polyps of colon& rectumDiverticulitis Crohns diseaseBPH Renal disease
-
8/8/2019 Relevance of Serum Tumor Markers
11/25
An oncofetal protein that was first discovered in1963 in the serum of mice with hepatomaNormal fetal protein synthesized by the liver, yolksac, and GIT that shares sequence homology with
albuminA major component of fetal plasma, reaching apeak concentration of 3mg/ml at 12 weeks ofgestation -- following birth, it clears rapidly fromthe circulation, having a half-life of 3.5 daysConcentration in adult serum
-
8/8/2019 Relevance of Serum Tumor Markers
12/25
Malignant conditions causingelevation of AFP aside from hepatoma
Teratocarcinoma of the testis andembryonal Ca (70%)Carcinoma of the pancreas (23%)Carcinoma of the stomach (18%)Carcinoma of the lung (7%)Carcinoma of the colon (5%)
*** In patients with hepatoma, theincidence of elevation of levels of AFPcorrelates with tumor burden
-
8/8/2019 Relevance of Serum Tumor Markers
13/25
A glycoprotein hormone with a MW of 45,000 daltonsComposed of 2 polypeptide chain alpha and betaCirculating half-life is 12 to 20 hoursNormally secreted by placental tissue with highestcirculating levels occurring at 60 days of gestationSignificant elevation occurs during pregnancy and inpatients with trophoblastic neoplasms ornonseminomatous germ cell tumorsIt maybe secreted in small amounts by the testis, pituitarygland and GITMaybe elevated in some benign conditions peptic ulcerdisease, inflammatory intestinal disease and cirrhosisIn patients with trophoblastic disease, levels of H CGcorrelate with tumor burden, prognosis of patient andresponse to therapy
-
8/8/2019 Relevance of Serum Tumor Markers
14/25
An antigen present on 80% of non-mucinous ovarian carcinomasDefined by a monoclonal antibody ( O C125)
that was generated by immunizinglaboratory mice with a cell line establishedfrom human ovarian carcinomaElevated in other cancers endometrial,
pancreatic, lung, breast, and colonElevated in benign conditions menstruation, pregnancy, endometriosis
-
8/8/2019 Relevance of Serum Tumor Markers
15/25
A monoclonal antibody generatedagainst a colon carcinoma cell line
to detect a monosialogangliosidefound in patients withgastrointestinal adenocarcinoma
Elevated in gastric cancer (21-42%), colon cancer (20-40%),pancreatic cancer (71-93%)
-
8/8/2019 Relevance of Serum Tumor Markers
16/25
Found in normal prostatic epithelium and secretions butnot in other tissuesIt is a glycoprotein whose function may be to lyse theseminal clotH ighly sensitive for the presence of prostatic cancerElevation correlated with stage and tumor volumePredictive of recurrence and response to treatmentH as prognostic value in patients with very high valuesprior to surgery are likely to relapsePresent in low concentrations in the blood of adult malesIt is produced by both normal and abnormal prostatecellsBenign elevations prostatitis and BP H
-
8/8/2019 Relevance of Serum Tumor Markers
17/25
-
8/8/2019 Relevance of Serum Tumor Markers
18/25
-
8/8/2019 Relevance of Serum Tumor Markers
19/25
-
8/8/2019 Relevance of Serum Tumor Markers
20/25
TumorTumorMarkersMarkers
CancersCancers What else? What else? SampleSample
B2M (BetaB2M (Beta--22microglobulinmicroglobulin
MultipleMultiplemyeloma,myeloma,lymphomaslymphomas
CrohnsCrohnsdisease,disease,hepatitishepatitis
BloodBlood
BTA (BladderBTA (Bladdertumor antigentumor antigen
BladderBladder GainingGainingacceptanceacceptance
UrineUrine
CA 72CA 72--44(Cancer(Cancerantigen 72antigen 72--44
O varianO varian No evidenceNo evidencethat is betterthat is betterthan CA 125than CA 125
BloodBlood
-
8/8/2019 Relevance of Serum Tumor Markers
21/25
TumorTumorMarkersMarkers
CancersCancers What else?What else? SampleSample
CalcitoninCalcitonin ThyroidThyroidMedullaryMedullarycarcinomacarcinoma
Also elevated in Also elevated inperniciousperniciousanemia andanemia andthyroiditsthyroidits
BloodBlood
NSE (NeuronNSE (Neuron--specificspecific enolaseenolase
Neuroblastoma,Neuroblastoma,small lungsmall lungcancercancer
May be betterMay be betterthan CEA for ff.than CEA for ff.this kind of lungthis kind of lungcancercancer
BloodBlood
NMP22NMP22 BladderBladder Not widely usedNot widely used UrineUrine
ProstateProstate- -specificspecificmembranemembraneantigen (PSMA)antigen (PSMA)
ProstateProstate Not widely used,Not widely used,levels increaselevels increasenormally withnormally withageage
BloodBlood
-
8/8/2019 Relevance of Serum Tumor Markers
22/25
-
8/8/2019 Relevance of Serum Tumor Markers
23/25
Ectopic tumor marker Primary tumor siteAFP Gastrointestinal, renal, breast, bladder &
ovary carcinoma
Calcitonin Carcinoma of lung, islet cell, carcinoid,breast and ovary, medullary carcinoma,phaeochromocytoma
Chromogranin A For endocrine tumors (medullary thyroidcarcinoma, anterior pituitary adenoma,pancreatic islet-cell carcinoma)
Beta-H CG Gastric & pancreatic carcinomas,hepatoma, ovarian adenocarcinoma,germinal-cell tumors of testis
hyroglobulin hyroid carcinoma
-
8/8/2019 Relevance of Serum Tumor Markers
24/25
-
8/8/2019 Relevance of Serum Tumor Markers
25/25
top related